Table 1.
Characters | level | Low expression of METTL18 | High expression of METTL18 | p | test |
---|---|---|---|---|---|
n | 186 | 185 | |||
T stage (%) | T1 | 99(53.8%) | 82(44.6%) | 0.206 | exact |
T2 | 42(22.8%) | 52(28.3%) | |||
T3 | 39(21.2%) | 41(22.3%) | |||
T4 | 4(2.2%) | 9(4.9%) | |||
N stage (%) | N0 | 121(98.4%) | 131(98.5%) | 1.000 | exact |
N1 | 2(1.6%) | 2(1.5%) | |||
M stage (%) | M0 | 128(99.2%) | 138(97.9%) | 0.624 | exact |
M1 | 1(0.8%) | 3(2.1%) | |||
Pathologic stage (%) | Stage I | 94(53.7%) | 77(44.8%) | 0.396 | exact |
Stage II | 40(22.9%) | 46(26.7%) | |||
Stage III | 39(22.3%) | 46(26.7%) | |||
Stage IV | 2(1.1%) | 3(1.7%) | |||
Residual tumor (%) | R0 | 167(96.0%) | 157(93.5%) | 0.390 | exact |
R1 | 7(4.0%) | 10(6.0%) | |||
R2 | 0(0.0%) | 1(0.6%) | |||
Histologic grade (%) | G1 | 33(17.9%) | 22(12.1%) | <0.001 | |
G2 | 105(57.1%) | 72(39.6%) | |||
G3 | 39(21.2%) | 83(45.6%) | |||
G4 | 7(3.8%) | 5(2.7%) | |||
Gender (%) | Female | 60(32.3%) | 61(33.0%) | 0.912 | exact |
Male | 126(67.7%) | 124(67.0%) | |||
Race (%) | Asian | 63(35.4%) | 95(52.5%) | 0.003 | exact |
Black or African American | 8(4.5%) | 9(5.0%) | |||
White | 107(60.1%) | 77(42.5%) | |||
Adjacent hepatic tissue inflammation (%) | Mild | 44(35.8%) | 55(49.5%) | 0.076 | |
None | 70(56.9%) | 47(42.3%) | |||
Severe | 9(7.3%) | 9(8.1%) | |||
Child-Pugh grade (%) | A | 113(91.1%) | 104(90.4%) | 0.907 | exact |
B | 10(8.1%) | 11(9.6%) | |||
C | 1(0.8%) | 0(0.0%) | |||
Vascular invasion (%) | No | 110(68.3%) | 96(62.3%) | 0.318 | |
Yes | 51(31.7%) | 58(37.7%) | |||
Tumor status (%) | Tumor free | 109(62.3%) | 92(52.0%) | 0.053 | exact |
With tumor | 66(37.7%) | 85(48.0%) | |||
TP53 status (%) | Mut | 42(23.3%) | 60(33.7%) | 0.040 | |
WT | 138(76.7%) | 118(66.3%) | |||
Age (%) | <=60 | 87(46.8%) | 90(48.9%) | 0.758 | |
>60 | 99(53.2%) | 94(51.1%) | |||
AFP (ng/ml) (%) | <=400 | 117(82.4%) | 96(70.6%) | 0.029 | |
>400 | 25(17.6%) | 40(29.4%) |